- Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia2011 | Faculty of Medicine in Hradec Králové
- Tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma2020 | First Faculty of Medicine
- Termination of the treatment in chronic myeloid leukemia - possi bility of stopping the tyrosine kinase inhibitors2017 | First Faculty of Medicine
- Discontinuation of biological therapy with tyrosine kinase inhibitors in chronic myeloid leukemia patients2014 | Faculty of Medicine in Pilsen
- Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield2015 | Faculty of Medicine in Pilsen
- Current approach for chronic myeloid leukemia treatment with tyrosin kinase inhibitors2016 | First Faculty of Medicine
- Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia2023 | First Faculty of Medicine
- Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy2024 | Publication without faculty affiliation
- MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma2018 | First Faculty of Medicine
- Nanomedicine of tyrosine kinase inhibitors2021 | Second Faculty of Medicine, Faculty of Science
- De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors2024 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Central Library of Charles University
- Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b(5) Activity2020 | Faculty of Science
- Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission2017 | Publication without faculty affiliation
- Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro2018 | Faculty of Science
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial2011 | Faculty of Medicine in Hradec Králové
- Direct salting-out assisted liquid-liquid extraction (SALLE) from human blood: Application for the analysis of tyrosine kinase inhibitors2020 | Faculty of Science
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial2018 | Publication without faculty affiliation
- Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera2007 | First Faculty of Medicine
- Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera2007 | Faculty of Physical Education and Sport
- Where does treatment of chronic myeloid leukemia target tyrosine kinase inhibitors?2018 | First Faculty of Medicine
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party2019 | Publication without faculty affiliation
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer2013 | Faculty of Medicine in Pilsen
- Long-term response to sequential treatment with tyrosine kinase inhibitors in a patient with EGFR+ adenocarcinoma2021 | Third Faculty of Medicine
- An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia2017 | First Faculty of Medicine, Second Faculty of Medicine
- An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia2017 | Central Library of Charles University
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine